Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Data ReadoutpositivesirexatamabPositive

AI Analysis

Summary

Leap Therapeutics announced publication of DeFianCe study results showing sirexatamab improved response, progression-free survival, and overall survival in DKK1-high second-line metastatic colorectal cancer patients when combined with bevacizumab, with DKK1 validated as a predictive biomarker.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

DeFianCe study results published in peer-reviewed journal; sirexatamab improved response, progression-free survival, and overall survival in DKK1-high 2L mCRC patients when added to bevacizumab; DKK1 established as continuous quantitative biomarker predicting benefit

Importance:6/10

Sentiment:

0.70

clinical_datapublicationbiomarkeroncologycombination_therapy

Related Companies

$LPTX

Read the original article

Published by PR Newswire Pharma on August 12, 2026 11:00 AM

Read Original